Compare IDEXX Laboratories, Inc. (IDXX) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Wayfair Inc — how do they compare? IDEXX Laboratories, Inc. trades at $570.26 (market cap $46.22B), while Wayfair Inc trades at $102.47 (market cap $14.14B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.3× Wayfair Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | W | |
|---|---|---|
Market Cap | $46.22B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $119.05 |
52-Week Low | $526.44 | $57.40 |
Enterprise Value | $47.12B | $16.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Wayfair (W) trades at $103.59, up 0.25% with bullish technical signals including a golden cross pattern. The company reported strong Q2 2026 results with EPS of $0.95 beating estimates and 7.5% revenue growth. Despite negative net margins, operating cash flow improved to $534 million in 2025. Analyst consensus leans bullish with 52% buy ratings and a $122 price target representing 18% upside potential.
The outlook remains positive driven by U.S. market share gains and margin expansion guidance, though risks include persistent losses and high debt levels. Technical support at $102 provides near-term protection while resistance at $105-108 marks the next challenge. The stock's momentum appears sustainable if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
